SLC9A1 and heart failure: Given the existing preclinical data demonstrating that pretreatment with NHE1 inhibitors or short-term use after hypotension can reduce cardiac dysfunction, clinical studies on patients with cardiac hypertrophy or heart failure need to confirm the optimal timing of drug administration.